Pharmacodynamics and tolerance of oral sustained release ritodrine

Frank R. Witter; Thomas J. Benedetti; Brent G. Petty; Arthur M. Feldman; Thomas A. Traiil; Judy Anderson

doi:10.1016/S0002-9378(88)80036-X

Pharmacodynamics and tolerance of oral sustained release ritodrine

Frank R. Witter, Thomas J. Benedetti, Brent G. Petty, Arthur M. Feldman, Thomas A. Traiil, Judy Anderson

School of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.

Original language	English (US)
Pages (from-to)	690-695
Number of pages	6
Journal	American journal of obstetrics and gynecology
Volume	159
Issue number	3
DOIs	https://doi.org/10.1016/S0002-9378(88)80036-X
State	Published - 1988

Keywords

Ritodrine
drug levels
oral sustained release
pharmacodynamics

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/S0002-9378(88)80036-X

Cite this

@article{24ab9f357583412d8d74eda823af2293,

title = "Pharmacodynamics and tolerance of oral sustained release ritodrine",

abstract = "A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.",

keywords = "Ritodrine, drug levels, oral sustained release, pharmacodynamics",

author = "Witter, {Frank R.} and Benedetti, {Thomas J.} and Petty, {Brent G.} and Feldman, {Arthur M.} and Traiil, {Thomas A.} and Judy Anderson",

note = "Funding Information: This work was supported by a g;rant from Kali-Duphar Laboratories, Inc., and by g;rant RR0035 from the National Institutes of Health, Division of Research Resources.",

year = "1988",

doi = "10.1016/S0002-9378(88)80036-X",

language = "English (US)",

volume = "159",

pages = "690--695",

journal = "American journal of obstetrics and gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "3",

}

TY - JOUR

T1 - Pharmacodynamics and tolerance of oral sustained release ritodrine

AU - Witter, Frank R.

AU - Benedetti, Thomas J.

AU - Petty, Brent G.

AU - Feldman, Arthur M.

AU - Traiil, Thomas A.

AU - Anderson, Judy

N1 - Funding Information: This work was supported by a g;rant from Kali-Duphar Laboratories, Inc., and by g;rant RR0035 from the National Institutes of Health, Division of Research Resources.

PY - 1988

Y1 - 1988

N2 - A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.

AB - A new oral sustained release formulation of ritodrine was tested for patient tolerance in this open study. The doses tested were 120 mg/day, 240 mg/day, and 360 mg/day. No objective toxicity was seen at any level. Doses of 120 mg/day and 240 mg/day were well-tolerated. Of the subjects who received the 360 mg/day dose, most tolerated it well.

KW - Ritodrine

KW - drug levels

KW - oral sustained release

KW - pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=0023802150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023802150&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(88)80036-X

DO - 10.1016/S0002-9378(88)80036-X

M3 - Article

C2 - 3421267

AN - SCOPUS:0023802150

SN - 0002-9378

VL - 159

SP - 690

EP - 695

JO - American journal of obstetrics and gynecology

JF - American journal of obstetrics and gynecology

IS - 3

ER -

Pharmacodynamics and tolerance of oral sustained release ritodrine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this